USG Tech Solutions Limited (BOM:532402)

Blueprint Medicines Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-6.44	-3.76	-2.59	-7.04	-49.9
Depreciation & Amortization	0.16	0.17	0.18	0.2	0.23
Loss (Gain) From Sale of Assets	-	-	-	0	-
Other Operating Activities	-12.69	15.77	-2.03	1.23	1.7
Change in Accounts Receivable	-0	-	0.01	-0.01	6.83
Change in Accounts Payable	-	0.04	-21.86	31.77	-1.72
Change in Other Net Operating Assets	0.56	0.17	2.36	-	-
Operating Cash Flow	-18.41	12.39	-23.94	26.15	-42.87
Investment in Securities	-	0	1.83	-9.33	43.73
Investing Cash Flow	-	0	1.83	-9.33	43.73
Long-Term Debt Issued	20.04	-	3.62	5.55	-
Long-Term Debt Repaid	-	-11.3	-	-	-
Net Debt Issued (Repaid)	20.04	-11.3	3.62	5.55	-
Other Financing Activities	-1.54	-1.37	-1.15	-1.03	-1.7
Financing Cash Flow	18.5	-12.67	2.48	4.52	-1.7
Miscellaneous Cash Flow Adjustments	-0.19	-	-	-	-0
Net Cash Flow	-0.09	-0.27	-19.63	21.34	-0.83
Free Cash Flow	-18.41	12.39	-23.94	26.15	-42.87
Free Cash Flow Margin	-	-	-871.00%	-	-128.56%
Free Cash Flow Per Share	-0.46	0.33	-0.65	0.67	-1.08
Cash Interest Paid	1.59	1.42	1.18	1.05	1.92
Levered Free Cash Flow	-3.35	-2.04	-42.57	27.55	-39.22
Unlevered Free Cash Flow	-2.35	-1.15	-41.84	28.2	-38.02
Change in Net Working Capital	-0.57	-0.17	40.91	-31.76	8.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.